CD274 and non-small cell lung carcinoma: In patients with metastatic non‐small cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression, there is still a lack of biomarkers to identify patients with maximum benefit from first‐line treatment with checkpoint inhibitor therapy (CIT) alone.